Tags : Targets

Biotech

Merck KGaA Collaborates with Artios Pharma for DNA Damage Cancer

Shots: Artios to receive $30M up front & near-term milestones, ~$860M/ target as option fee along with royalties on sales of each commercialized product. Additionally, Artios has opt-in rights for joint development & commercialization of the programs Merck has the right to opt into exclusive development & commercialization of compounds on up to 8 targets […]Read More

Biotech

Egle Identifies First Novel Regulatory T-cell Targets Under its Collaboration

Shots: Egle has achieved the first milestone in its research agreement with Takeda, signed in June’2020. Egle will validate novel tumor-infiltrating regulatory T-cell targets while Takeda will develop the potential therapies Egle has leveraged its unique bioinformatic & translational capabilities to identify targets Following the achievement of the target identification, Egle will receive an R&D […]Read More